Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer
NCT ID: NCT03015298
Last Updated: 2017-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2017-01-31
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
NCT06945432
Role of 18F-FDG PET/CT in Gastric Cancer
NCT05687552
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05392205
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034
Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
NCT06543108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gastric cancer
Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
PET/MRI
The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
PET/CT
At the next day of PET/MRI examination,A PET/CT examination will be performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/MRI
The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
PET/CT
At the next day of PET/MRI examination,A PET/CT examination will be performed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No previous treatment history for gastric cancer
3. Without complications of obstruction,bleeding and so on
4. Without severe diabetes,the levels of blood glucose \<6.2 mmol/L .
5. No cardiac pacemarker,never stimulator or other metal substitute materials in vivo.
Exclusion Criteria
2. Suffering acute inflammatory disease
3. History of chemo-radiotherapy
4. Suffering prostate hyperplasia,glaucoma
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lin Chen
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianxin Cui, Doctor
Role: STUDY_DIRECTOR
the Chinese PLA General Hospital
Yi Liu
Role: PRINCIPAL_INVESTIGATOR
the Chinese PLA General Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Experiment20160901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.